Retour aux projets

16771.3 PFLS-LS

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Résumé

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Textes supplémentaires

Abstract

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.

Participants

Bernd Wollscheid

Kontaktperson

wbernd@ethz.ch

ETH Zürich Bernd Wollscheid Auguste-Piccard-Hof 1 8093 Zürich ZH CH

Ralph Schiess

Wirtschaftspartner

schiess@proteomedix.com

ProteoMediX AG Ralph Schiess Wagistrasse 23 8952 Schlieren ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2015-03-31
Date de fin
2017-12-31
Coûts totaux approuvés
CHF 738810.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%